U.S. markets close in 4 hours 33 minutes

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
76.92-1.64 (-2.09%)
As of 11:27AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close78.56
Open78.32
Bid76.73 x 1100
Ask76.82 x 800
Day's Range76.26 - 78.58
52 Week Range62.48 - 110.37
Volume356,450
Avg. Volume1,192,430
Market Cap16.91B
Beta (5Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)-1.36
Earnings DateMay 03, 2021 - May 07, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est105.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial
    PR Newswire

    Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

    Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA). Both doses of baricitinib met the primary efficacy endpoint at Week 36, demonstrating a statistically significant improvement in scalp hair regrowth compared to those randomized to placebo. AA is an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress. Baricitinib has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of AA. This classification aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over already available therapies on a clinically significant endpoint(s). There are currently no FDA-approved treatments for AA.

  • Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)
    Business Wire

    Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)

    Incyte Announces Validation by the EMA of Marketing Authorization Application for Retifanlimab as a Treatment for Squamous Cell Anal Carcinoma (SCAC)

  • Incyte Says FDA Grants Priority Review For Eczema Cream; Street Sees 20% Upside
    SmarterAnalyst

    Incyte Says FDA Grants Priority Review For Eczema Cream; Street Sees 20% Upside

    Incyte announced that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of its ruxolitinib cream. Shares of the biopharmaceutical company declined around 1.2% to close at $80.54 on Feb. 19. A priority review voucher (PRV) was submitted by Incyte (INCY) along with the NDA application, which shortens the review period by four months. The ruxolitinib cream is a selective JAK1/JAK2 inhibitor for topical application and is targeted to treat atopic dermatitis (AD), a type of eczema. Incyte said that the NDA was supported by clinical trial data, which showed that the application of ruxolitinib cream was safe and effective in patients with AD in individuals 12 years and older who are undergoing topical therapy. About 21 million individuals in the US are suffering from this chronic skin disease. (See Incyte stock analysis on TipRanks) Incyte Group Vice President Jim Lee said, “We are grateful to the people living with atopic dermatitis whose participation in our clinical trials helped generate the evidence to support this regulatory submission, and we look forward to working with the FDA as we seek to bring forward a new topical treatment for people living with this chronic skin disease.” On Feb. 9, Mizuho Securities analyst Mara Goldstein reiterated a Hold rating on the stock with a price target of $95 (18% upside potential). The analyst expects “positive signs from” the company’s “pipeline and strong cash flow from JAKAFI,” but is cautious, “on greater valuation expansion for the shares.” The rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating. That’s based on 4 analysts suggesting a Buy, 4 analysts recommending a Hold, and 1 analyst suggesting a Sell. The average analyst price target of $97 implies around 20% upside potential to current levels. Shares have gained about 1.6% over the past year. Incyte scores an 8 of 10 from TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations. Related News: Nurix Says FDA Approves New Drug Application For Leukemia Trial; Street Is Bullish CVS Health Posts Better-Than-Expected 4Q Results; Shares Gain Pre-Market Novavax Extends SK Bioscience Partnership For Supply Of 40M COVID-19 Vaccine Doses More recent articles from Smarter Analyst: KBR’s 4Q Profit Tops Analysts' Estimates; Street Is Bullish Ayala Pharmaceuticals To Raise $25M Via Private Stock Placement; Shares Pop 16% Enerplus’ Quarterly Profit Lags Estimates Amid Lower Production Monday’s Pre-Market: Here’s What You Need To Know Before The Market Opens